Table 1.
Baseline patient characteristics by comorbidity
| Any | Arthritis | Diabetes | Vascular | |||||
|---|---|---|---|---|---|---|---|---|
| No | Yes | No | Yes | No | Yes | No | Yes | |
| (n = 78) | (n = 233) | (n = 139) | (n = 172) | (n = 265) | (n = 46) | (n = 199) | (n = 112) | |
| Placebo: | 26 | 78 | 49 | 55 | 93 | 11 | 60 | 44 |
| Duloxetine: | 52 | 155 | 90 | 117 | 172 | 35 | 139 | 68 |
| Characteristics | ||||||||
| Gender, female, n (%) | 35 (44.9) | 150 (64.4) | 63 (45.3) | 122 (70.9) | 164 (61.9) | 21 (45.7) | 118 (59.3) | 67 (59.8) |
| Age, years, mean (SD) | 71.3 (5.3) | 73.4 (5.7) | 72.7 (5.6) | 73.0 (5.8) | 72.9 (5.8) | 73.0 (5.1) | 72.2 (5.7) | 74.1 (5.5) |
| Age range, years | 65–88 | 65–89 | 65–88 | 65–89 | 65–89 | 65–85 | 65–89 | 65–86 |
| Weight, kg, mean (SD) | 79.1 (17.4) | 80.4 (18.4) | 80.2 (16.1) | 80.0 (19.6) | 78.8 (18.0) | 87.5 (17.5) | 78.9 (18.0) | 82.1 (18.2) |
| Ethnicity, n (%) | ||||||||
| Caucasian | 60 (76.9) | 183 (78.5) | 105 (75.5) | 138 (80.2) | 210 (79.2) | 33 (71.7) | 154 (77.4) | 89 (79.5) |
| Hispanic | 13 (16.7) | 35 (15.0) | 25 (18.0) | 23 (13.4) | 37 (14.0) | 11 (23.9) | 35 (17.6) | 13 (11.6) |
| African descent | 3 (3.8) | 14 (6.0) | 6 (4.3) | 11 (6.4) | 15 (5.7) | 2 (4.3) | 8 (4.0) | 9 (8.0) |
| Western Asian | 1 (1.3) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 1 (0.4) | 0 (0.0) | 1 (0.5) | 0 (0.0) |
| Other | 1 (1.3) | 1 (0.4) | 2 (1.4) | 0 (0.0) | 2 (0.8) | 0 (0.0) | 1 (0.5) | 1 (0.9) |
| Psychiatric profile, mean (SD)* | ||||||||
| Composite Cognitive Score | 23.9 (8.0) | 22.5 (6.6) | 22.6 (7.3) | 23.0 (6.7) | 23.2 (7.1) | 21.1 (6.2) | 23.4 (7.5) | 21.9 (5.8) |
| HAMD17 total (visit 1) | 22.5 (3.4) | 22.2 (3.8) | 22.2 (3.6) | 22.3 (3.8) | 22.3 (3.7) | 21.9 (3.8) | 22.5 (3.8) | 21.7 (3.4) |
| HAMD17 total (randomisation) | 19.2 (5.0) | 18.7 (4.6) | 19.0 (4.7) | 18.7 (4.7) | 18.8 (4.7) | 19.4 (4.7) | 18.9 (5.0) | 18.7 (4.2) |
| GDS total | 17.5 (7.5) | 17.7 (7.0) | 17.4 (7.1) | 17.9 (7.1) | 17.6 (7.2) | 17.9 (6.8) | 18.1 (7.1) | 16.8 (7.1) |
| Duration of current episode, weeks | 59.8 (89.3) | 54.3 (85.3) | 61.8 (101.5) | 50.7 (71.4) | 56.9 (88.6) | 48.8 (71.6) | 50.3 (70.0) | 65.2 (108.7) |
| Number of previous episodes | 4.5 (6.3) | 5.8 (16.4) | 5.9 (17.7) | 5.1 (11.2) | 5.3 (13.9) | 6.4 (17.8) | 4.7 (9.9) | 6.7 (20.3) |
| VAS overall pain severity | 21.9 (21.6) | 34.4 (27.6) | 22.5 (21.7) | 38.3 (28.3) | 30.6 (26.3) | 35.0 (28.9) | 32.9 (27.7) | 28.3 (24.7) |
| SF-36 physical component | 46.0 (11.2) | 40.0 (10.3) | 44.6 (11.1) | 39.0 (9.8) | 42.3 (10.8) | 37.3 (9.9) | 42.5 (10.7) | 39.9 (10.9) |
| SF-36 mental component | 31.6 (12.3) | 32.4 (10.5) | 32.3 (12.0) | 32.2 (10.1) | 32.1 (10.8) | 33.0 (12.0) | 31.7 (11.1) | 33.1 (10.8) |
*
Total sample sizes for variables shown range from 304 to 311.